Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.

CAR-T cells PCTS cytotoxic T cells ex vivo models immunotherapy organotypic tumor slices precision-cut tumor slices solid tumors

Journal

Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489

Informations de publication

Date de publication:
06 Apr 2022
Historique:
received: 27 02 2022
revised: 25 03 2022
accepted: 01 04 2022
entrez: 25 4 2022
pubmed: 26 4 2022
medline: 26 4 2022
Statut: epublish

Résumé

Precision-cut tumor slices (PCTS) have recently emerged as important ex vivo human tumor models, offering the opportunity to study individual patient responses to targeted immunotherapies, including CAR-T cell therapies. In this review, an outline of different human tumor models available in laboratory settings is provided, with a focus on the unique characteristics of PCTS. Standard PCTS generation and maintenance procedures are outlined, followed by an in-depth overview of PCTS utilization in preclinical research aiming to better understand the unique functional characteristics of cytotoxic T cells within human tumors. Furthermore, recent studies using PCTS as an ex vivo model for predicting patient responses to immunotherapies and other targeted therapies against solid tumors are thoroughly presented. Finally, the advantages and limitations of the PCTS models are discussed. PCTS are expected to gain momentum and be fully utilized as a significant tool towards better patient stratification and personalized medicine.

Identifiants

pubmed: 35466279
pii: antib11020026
doi: 10.3390/antib11020026
pmc: PMC9036232
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Sci Data. 2017 Nov 21;4:170170
pubmed: 29160867
J Pharm Bioallied Sci. 2014 Jan;6(1):2-9
pubmed: 24459397
Nat Rev Clin Oncol. 2020 Jun;17(6):341-348
pubmed: 32112054
NPJ Precis Oncol. 2020 May 19;4:12
pubmed: 32435696
STAR Protoc. 2021 Jun 02;2(2):100574
pubmed: 34142099
Br J Cancer. 2020 Mar;122(5):601-602
pubmed: 31919403
Eur Respir J. 2021 Jul 1;58(1):
pubmed: 34215663
J Vis Exp. 2017 Dec 27;(130):
pubmed: 29364247
Inflammation. 2012 Apr;35(2):560-5
pubmed: 21603970
Cancer Immunol Res. 2021 Dec;9(12):1425-1438
pubmed: 34686489
J Pharmacol Exp Ther. 2010 Mar;332(3):821-8
pubmed: 19952304
Cancer Immunol Res. 2021 May;9(5):583-597
pubmed: 33619119
Oncoimmunology. 2019 Jul 13;8(9):e1638211
pubmed: 31428531
Clin Cancer Res. 2020 Aug 1;26(15):4107-4119
pubmed: 32299813
Elife. 2021 Aug 18;10:
pubmed: 34406120
Cancers (Basel). 2020 Dec 28;13(1):
pubmed: 33379189
Oncoimmunology. 2017 May 25;6(7):e1333210
pubmed: 28811976
Clin Cancer Res. 2016 Dec 15;22(24):6021-6030
pubmed: 27259561
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6
pubmed: 20404174
Br J Cancer. 2019 Jul;121(2):101-108
pubmed: 31231121
Cancer Res. 2016 Apr 1;76(7):1757-69
pubmed: 26921343
Cancers (Basel). 2020 Jan 17;12(1):
pubmed: 31963500
Eur Respir J. 2021 Jul 1;58(1):
pubmed: 33361096
J Vis Exp. 2021 Jun 22;(172):
pubmed: 34251366
Trends Immunol. 2019 Aug;40(8):735-747
pubmed: 31255505
Cell Death Differ. 2021 Jan;28(1):68-83
pubmed: 33223522
Oncotarget. 2019 Jan 22;10(7):785-797
pubmed: 30774780
Sci Rep. 2015 Dec 09;5:17187
pubmed: 26647838
J Clin Invest. 2012 Mar;122(3):899-910
pubmed: 22293174
Cancers (Basel). 2021 Oct 05;13(19):
pubmed: 34638476
Arch Toxicol. 2019 Dec;93(12):3549-3583
pubmed: 31754732
Xenobiotica. 2013 Jan;43(1):2-7
pubmed: 23009272
Cold Spring Harb Protoc. 2017 Jun 1;2017(6):pdb.prot094011
pubmed: 28572189
Pharmacol Res. 2020 Sep;159:104876
pubmed: 32422340
Future Sci OA. 2017 Mar 27;3(2):FSO190
pubmed: 28670477
Int J Pharm. 2011 Oct 31;419(1-2):33-42
pubmed: 21782910
J Immunother Cancer. 2018 Sep 4;6(1):87
pubmed: 30180905
J Vis Exp. 2017 Jul 20;(125):
pubmed: 28784966
Front Oncol. 2021 Nov 30;11:782766
pubmed: 34917509
Neuro Oncol. 2013 Jun;15(6):670-81
pubmed: 23576601
Am J Physiol Lung Cell Mol Physiol. 2021 Feb 1;320(2):L232-L240
pubmed: 33112185
Am J Respir Cell Mol Biol. 2020 Jun;62(6):681-691
pubmed: 31991090
Ann Transl Med. 2020 Feb;8(4):114
pubmed: 32175407
Oncoimmunology. 2019 Oct 10;8(12):e1670019
pubmed: 31741771
Cytotechnology. 2009 Dec;61(3):145-52
pubmed: 20091220
Biotechnol Bioeng. 2019 Jan;116(1):206-226
pubmed: 30367820
Front Immunol. 2015 Oct 12;6:500
pubmed: 26528284
Clin Cancer Res. 2019 Jul 1;25(13):3934-3945
pubmed: 30940657
BMC Cancer. 2019 Nov 1;19(1):1030
pubmed: 31675944
Prostate. 2019 Mar;79(4):390-402
pubmed: 30520109
Gastroenterology. 2016 May;150(5):1147-1159.e5
pubmed: 26874076
Clin Exp Immunol. 2000 Mar;119(3):441-8
pubmed: 10691915
Adv Sci (Weinh). 2021 Nov;8(22):e2101176
pubmed: 34605222
Sci Rep. 2020 Jun 3;10(1):9070
pubmed: 32493953
Nat Commun. 2019 Sep 27;10(1):4401
pubmed: 31562311
Nat Commun. 2019 Sep 5;10(1):3991
pubmed: 31488816
BMC Cancer. 2016 Feb 09;16:78
pubmed: 26860465
Front Vet Sci. 2021 Jun 04;8:686088
pubmed: 34150901
Biol Proced Online. 2015 Jan 07;17(1):2
pubmed: 25657614
Gastroenterol Rep (Oxf). 2018 Nov;6(4):243-245
pubmed: 30430011

Auteurs

Paraskevi Dimou (P)

Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, UK.

Sumita Trivedi (S)

Division of Hematology and Medical Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.

Maria Liousia (M)

Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.

Reena R D'Souza (RR)

Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, UK.

Astero Klampatsa (A)

Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, UK.

Classifications MeSH